LENZ Therapeutics (LENZ) Long-Term Investments (2022)

LENZ Therapeutics (LENZ) reported Long-Term Investments of $15.3 million for Q4 2022, up 14.32% quarter-over-quarter from $13.4 million in Q3 2022.

LENZ Therapeutics (LENZ) Long-Term Investments (2022) Analysis & Trends

LENZ Therapeutics (LENZ) has 1 years of Long-Term Investments data on file, last reported at $15.3 million in Q4 2022.

Long-Term Investments for Q4 2022 came in at $15.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $15.3 million (changed N/A YoY), and the FY2022 annual result was $15.3 million, changed N/A from the prior year.
Long-Term Investments climbed to $15.3 million in Q4 2022 per LENZ's latest filing, from $13.4 million in the prior quarter.
Over five years, Long-Term Investments peaked at $15.3 million in Q4 2022 and troughed at $6.0 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	5.75 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	LENZ Therapeutics	192.19 Mn	192.19 Mn	825,000.00	-

Download Data